Senti Biosciences Stock Performance

SNTI Stock  USD 0.81  0.06  6.90%   
The entity has a beta of 2.03, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Senti Biosciences will likely underperform. At this point, Senti Biosciences has a negative expected return of -0.69%. Please make sure to validate Senti Biosciences' total risk alpha, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Senti Biosciences performance from the past will be repeated at some point in the near future.

Risk-Adjusted Performance

Weakest

 
Weak
 
Strong
Over the last 90 days Senti Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in March 2026. The recent confusion may also be a sign of long-lasting up-swing for the firm traders. ...more
Last Split Factor
1:10
Last Split Date
2024-07-18
1
Senti Biosciences Coverage Initiated by Analysts at Leerink Partners
11/21/2025
2
Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MR...
12/09/2025
3
Senti Biosciences Inc. Stock Price Live Quotes Charts NASDAQ - StocksToTrade
12/15/2025
4
Promising Biotech Stocks To Keep An Eye On - December 9th - MarketBeat
12/30/2025
5
Breakouts Watch Should I hold or sell Senti Biosciences Inc stock in 2025 - moha.gov.vn
01/13/2026
6
Senti Biosciences, Inc. Given Average Rating of Moderate Buy by Brokerages
01/15/2026
7
Acquisition by Lu Timothy K of 642358 shares of Senti Biosciences subject to Rule 16b-3
01/16/2026
8
Can Senti Biosciences Inc sustain its profitability - 2025 Year in Review Verified Momentum Stock Ideas - baoquankhu1.vn
01/22/2026
9
Disposition of 4191 shares by Lu Timothy K of Senti Biosciences subject to Rule 16b-3
02/02/2026
10
Aug Movers Does Senti Biosciences Inc have a sustainable dividend - 2025 Winners Losers Verified Momentum Stock Alerts - baoquankhu1.vn
02/04/2026
11
Senti Biosciences Completes Enrollment in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
02/11/2026
Begin Period Cash Flow39.4 M
Total Cashflows From Investing Activities34 K

Senti Biosciences Relative Risk vs. Return Landscape

If you would invest  145.00  in Senti Biosciences on November 15, 2025 and sell it today you would lose (64.00) from holding Senti Biosciences or give up 44.14% of portfolio value over 90 days. Senti Biosciences is currently does not generate positive expected returns and assumes 7.096% risk (volatility on return distribution) over the 90 days horizon. In different words, 63% of stocks are less volatile than Senti, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Senti Biosciences is expected to under-perform the market. In addition to that, the company is 9.14 times more volatile than its market benchmark. It trades about -0.1 of its total potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.13 per unit of volatility.

Senti Biosciences Target Price Odds to finish over Current Price

The tendency of Senti Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 0.81 90 days 0.81 
about 89.33
Based on a normal probability distribution, the odds of Senti Biosciences to move above the current price in 90 days from now is about 89.33 (This Senti Biosciences probability density function shows the probability of Senti Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 2.03 . This usually implies as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Senti Biosciences will likely underperform. Additionally Senti Biosciences has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   Senti Biosciences Price Density   
       Price  

Predictive Modules for Senti Biosciences

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Senti Biosciences. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Senti Biosciences' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.040.767.86
Details
Intrinsic
Valuation
LowRealHigh
0.173.4710.57
Details
1 Analysts
Consensus
LowTargetHigh
10.4711.5012.77
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-0.71-0.64-0.51
Details

Senti Biosciences Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Senti Biosciences is not an exception. The market had few large corrections towards the Senti Biosciences' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Senti Biosciences, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Senti Biosciences within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-1.21
β
Beta against Dow Jones2.03
σ
Overall volatility
0.45
Ir
Information ratio -0.16

Senti Biosciences Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Senti Biosciences for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Senti Biosciences can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Senti Biosciences generated a negative expected return over the last 90 days
Senti Biosciences has high historical volatility and very poor performance
Senti Biosciences has some characteristics of a very speculative penny stock
Senti Biosciences has a very high chance of going through financial distress in the upcoming years
Net Loss for the year was (52.79 M) with loss before overhead, payroll, taxes, and interest of (37.6 M).
Senti Biosciences currently holds about 140.78 M in cash with (41.4 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.24, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Senti Biosciences has a poor financial position based on the latest SEC disclosures
Roughly 57.0% of the company outstanding shares are owned by corporate insiders
Latest headline from globenewswire.com: Senti Biosciences Completes Enrollment in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Senti Biosciences Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Senti Stock often depends not only on the future outlook of the current and potential Senti Biosciences' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Senti Biosciences' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding4.6 M
Cash And Short Term Investments48.3 M

Senti Biosciences Fundamentals Growth

Senti Stock prices reflect investors' perceptions of the future prospects and financial health of Senti Biosciences, and Senti Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Senti Stock performance.

About Senti Biosciences Performance

By evaluating Senti Biosciences' fundamental ratios, stakeholders can gain valuable insights into Senti Biosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Senti Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Senti Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.62)(0.65)
Return On Capital Employed(0.83)(0.87)
Return On Assets(0.62)(0.65)
Return On Equity(2.37)(2.25)

Things to note about Senti Biosciences performance evaluation

Checking the ongoing alerts about Senti Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Senti Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Senti Biosciences generated a negative expected return over the last 90 days
Senti Biosciences has high historical volatility and very poor performance
Senti Biosciences has some characteristics of a very speculative penny stock
Senti Biosciences has a very high chance of going through financial distress in the upcoming years
Net Loss for the year was (52.79 M) with loss before overhead, payroll, taxes, and interest of (37.6 M).
Senti Biosciences currently holds about 140.78 M in cash with (41.4 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.24, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Senti Biosciences has a poor financial position based on the latest SEC disclosures
Roughly 57.0% of the company outstanding shares are owned by corporate insiders
Latest headline from globenewswire.com: Senti Biosciences Completes Enrollment in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Evaluating Senti Biosciences' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Senti Biosciences' stock performance include:
  • Analyzing Senti Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Senti Biosciences' stock is overvalued or undervalued compared to its peers.
  • Examining Senti Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Senti Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Senti Biosciences' management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Senti Biosciences' stock. These opinions can provide insight into Senti Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Senti Biosciences' stock performance is not an exact science, and many factors can impact Senti Biosciences' stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for Senti Stock analysis

When running Senti Biosciences' price analysis, check to measure Senti Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Senti Biosciences is operating at the current time. Most of Senti Biosciences' value examination focuses on studying past and present price action to predict the probability of Senti Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Senti Biosciences' price. Additionally, you may evaluate how the addition of Senti Biosciences to your portfolios can decrease your overall portfolio volatility.
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities